FRSH
CRWD
ABBV

Roxanne S. Austin

Known title: DirectorCIK: 0001061632

Roxanne S. Austin's purchase track record

Roxanne S. Austin has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
1/5/2023CRWD$4.90M+34.7%+51.3%
12/27/2022CRWD$2.49M+27.8%+43.3%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 11, 2026

Freshworks added to S&P SmallCap 600 as shares rise. Freshworks will join the S&P SmallCap 600 index, and the news has moved the stock higher. The inclusion could raise the company's profile among investors. The firm also plans to release its third‑quarter 2026 results on November 3, which may affect trading activity. Recent price action reflects a breakout pattern on the chart.

this person other insiders at FRSH

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

CrowdStrike Shares Drop 7% Amid Cybersecurity Sector Rotation. CrowdStrike shares fell 7% on Friday as investors reassess the AI thesis and cybersecurity valuations. Recent commentary notes a split in the sector between platform and point solutions, with some stocks facing pressure. The stock is currently trading near its support level, reflecting broader market uncertainty.

this person other insiders at CRWD

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.

this person other insiders at ABBV

Transaction History

FRSH▲ Buy$20K
CRWD▼ Sell$7.1M
CRWD▲ Buy$0
CRWD▼ Sell$4.8M
FRSH▲ Buy$0
CRWD▲ Buy$0
ABBV▲ Buy$0
FRSH▲ Buy$20K
FRSH▲ Buy$0
FRSH▲ Buy$0
FRSH▲ Buy$0
CRWD▲ Buy$0
CRWD▼ Sell$2.3M
CRWD▼ Sell$2.6M
CRWD▲ Buy$0
CRWD▼ Sell$282K
CRWD▼ Sell$2.5M
CRWD▼ Sell$2.5M
CRWD▼ Sell$2.5M
CRWD▲ Buy$0
CRWD▲ Buy$0
CRWD▲ Buy$0
CRWD▼ Sell$2.4M
CRWD▲ Buy$0
CRWD▼ Sell$2.4M
CRWD▲ Buy$0
CRWD▼ Sell$4.8M
CRWD▲ Buy$0
CRWD▼ Sell$3.4M
FRSH▼ Sell$93K
ABBV▲ Buy$0
FRSH▼ Sell$76K
CRWD▲ Buy$0
CRWD▼ Sell$1.9M
FRSH▲ Buy$0
FRSH▼ Sell$96K
FRSH▼ Sell$111K
FRSH▼ Sell$99K
FRSH▲ Buy$0
CRWD▲ Buy$0
CRWD▼ Sell$1.9M
FRSH▼ Sell$109K
FRSH▼ Sell$104K
FRSH▼ Sell$70K
FRSH▲ Buy$0
FRSH▼ Sell$72K
FRSH▼ Sell$71K
FRSH▼ Sell$79K
FRSH▼ Sell$79K
FRSH▲ Buy$0
CRWD▼ Sell—
CRWD▼ Sell$2.0M
CRWD▼ Sell—
CRWD▼ Sell$3.9M
CRWD▲ Buy$0
FRSH▼ Sell$320K
ABBV▲ Buy$0
FRSH▼ Sell$0
FRSH▼ Sell$0
FRSH▲ Buy$0
FRSH▼ Sell$136K
FRSH▼ Sell$142K
FRSH▲ Buy$0
FRSH▼ Sell$127K
FRSH▼ Sell$114K
CRWD▼ Sell$926K
CRWD▼ Sell$925K
FRSH▼ Sell$121K
CRWD▼ Sell$860K
CRWD▼ Sell$861K
FRSH▲ Buy$0
FRSH▼ Sell$139K
FRSH▼ Sell$135K
CRWD▼ Sell$3.1M
CRWD▼ Sell$453K
CRWD▼ Sell$300K
CRWD▼ Sell$4.5M
CRWD▼ Sell$2.3M
CRWD▼ Sell$767K
CRWD▼ Sell$758K
FRSH▼ Sell$102K
FRSH▼ Sell$138K
FRSH▲ Buy$0
CRWD▲ Buy$0
FRSH▼ Sell$397K
ABBV▲ Buy$0
FRSH▼ Sell$0
FRSH▼ Sell$0
FRSH▲ Buy$0
ABBV▼ Sell$1.5M
CRWD▲ Buy$1.5M
CRWD▲ Buy$1.9M
CRWD▲ Buy$1.5M
FRSH▲ Buy$0
CRWD▲ Buy$993K
CRWD▲ Buy$1.5M
FRSH▲ Buy$0
CRWD▼ Sell—
FRSH▲ Buy$0
CRWD▲ Buy$0
CRWD▼ Sell—
ABBV▲ Buy$0
FRSH▲ Buy$0
CRWD▼ Sell—
FRSH▲ Buy$0
CRWD▼ Sell—
ABBV▼ Sell$2.3M
ABBV▼ Sell$2.9M
ABBV▼ Sell$789K
ABBV▼ Sell$2.3M
CRWD▼ Sell$2.7M
CRWD▼ Sell—

We use analytics to understand how market-wall is used. No personal data is sold.